4KB Stock Chart & Stats
€307.60
€0.20(0.07%)
At close: 4:00 PM EDT
€307.60
€0.20(0.07%)
Day’s Range― - ―
52-Week Range€158.30 - €330.20
Previous CloseN/A
Volume40.00
Average Volume (3M)2.00
Market Cap
€8.31B
Enterprise Value€10.56B
Total Cash (Recent Filing)€845.63M
Total Debt (Recent Filing)€8.85M
Price to Earnings (P/E)37.9
Beta0.04
Next Earnings
Nov 02, 2026EPS Estimate
1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.27
Shares Outstanding29,598,837
10 Day Avg. Volume2
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€359.43Price Target Upside16.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)6.62
Revenue Forecast (FY)€443.92M
Bulls Say, Bears Say
Bulls Say
Revenue And ProfitabilityKrystal has achieved a strong commercial inflection, with revenue scaling from $50.7M in 2023 to $389.1M in 2025 and $440.5M TTM. High net and EBIT margins indicate that VYJUVEK adoption is translating into substantial operating earnings.
Cash Generation And Balance SheetVery low leverage and strong cash generation give Krystal considerable financial flexibility. TTM free cash flow of $257.8M and debt of only $1.8M support continued investment in clinical programs, commercial expansion, and regulatory activity without meaningful balance-sheet strain.
Pipeline And Regulatory ExpansionKB113 provides an encouraging expansion opportunity beyond VYJUVEK, with regression in more than 80% of assessed lesions and responses in injected and non-injected tumors. FDA discussions create a path toward advancing a potentially broader dermatologic oncology application.
Bears Say
International Access And ReimbursementInternational growth remains exposed to country-specific reimbursement decisions and administration hurdles. Pending pricing outcomes and operational friction in major markets can delay patient access, create revenue variability, and reduce the near-term contribution of VYJUVEK outside the United States.
Historical Earnings And Cash-Flow VolatilityAlthough current results are strong, the recent profitability transition has not yet established a long operating history of stability. Earlier negative cash flow and weak operating profit show that spending or commercialization changes could still produce meaningful variability in future earnings and liquidity generation.
Early-Stage Pipeline UncertaintySeveral pipeline programs remain supported by small early-stage cohorts, limiting statistical power and confidence in efficacy, safety, and commercial timing. Until larger studies or registrational data mature, development setbacks could reduce the value and diversification expected from the broader pipeline.
Krystal Biotech News
4KB FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was €158.30 and its highest was €330.20 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is €8.31B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Nov 02, 2026 which is in 5 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Aug 03, 2026. The company reported €1.609 earnings per share for the quarter, beating the consensus estimate of €1.529 by €0.08.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.61.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 29,598,837 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of €1.609 in its last earnings report, beating expectations of €1.529. Following the earnings report the stock price went down -4.927%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in DE:4KB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€359.43 (16.85% Upside)
€359.43 (16.85% Upside)
Blogger Sentiment
Bullish
DE:4KB Sentiment 75%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €23.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.51%
12-Months-Change
Fundamentals
Return on Equity
19.34%
Trailing 12-Months
Asset Growth
31.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
4KB Company Deck
4KB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial highlights — double‑digit revenue growth (+24% YoY), improved gross margin (95%), expanded U.S. reimbursement (>730 approvals), robust cash (> $1.1B), and advancing clinical programs with several near‑term readouts and encouraging oncology signals. Lowlights were primarily operational and timing risks tied to international pricing/reimbursement (notably a German accrual that depressed reported EMEA revenue), country‑specific access constraints, modest increases in G&A, and the small size/early stage of several repeat‑dose studies. Overall, the positives around revenue, profitability, cash position, and pipeline momentum outweigh the near‑term access and timing headwinds, supporting a constructive outlook.View all DE:4KB earnings summaries4KB Stock 12 Month Forecast
Average Price Target
€359.43
▲(16.85% Upside)
Technical Analysis
Sarepta Therapeutics
―
Precigen
―
Ultragenyx Pharmaceutical
―
uniQure
―
Taysha Gene Therapies
―